Nasdaq · Biotech stocks database
BDRX — Biodexa Pharmaceuticals plc ☆
BDRX (Biodexa Pharmaceuticals plc) stock: $2.47, $1.3M market cap, $11.4M cash, -$10.0M EV, $22.0M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
We are a clinical stage biopharmaceutical company developing a pipeline of innovative products focused on the treatment or prevention of gastrointestinal cancers including gastrointestinal stromal tumors, or GIST and familial adenomatous polyposis, or FAP. In April 2024 we licensed eRapa, a proprietary formulation of rapamycin, from Rapamycin Holdings, Inc. d/b/a Emtora Biosciences, Inc., or Emtora.
Source: 20-F FY2025 via SEC EDGAR
Balance sheet
Cash $11.4M Debt $0.1M Net cash $11.3M Enterprise value -$10.0M Basic shares 4.1M shares Fully diluted shares 8.9M shares Fully diluted market cap $22.0M Cash per share $2.76 Quarterly burn $1.8M Cash runway 6.4 quarters
Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.
Share structure
Cap table as of 2026-09-24.
Price history Loading BDRX daily closes…
Loading price history…
Next catalyst eRapa · Est. Feb 14, 2027 · quarter midpoint · guided in 8 wks All upcoming catalysts →
Upcoming catalysts Expected Drug Phase Indication Mgmt guide GUIDED Est. Feb 14, 2027 in 8 wks quarter midpoint
eRapaPhase 3 interim futility analysis in familial adenomatous polyposis
Phase 3 familial adenomatous polyposis Q1 2027
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Asset data not yet available for this company.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.